PLX-4032 is a highly selective inhibitor of BRAF kinase activity with an IC₅₀ of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors. PLX-4032 has been shown to selectively inhibit the RAF/MEK/ERK pathway in BRAF mutant cells and induce regression of BRAF mutant xenographs. PLX4032 has also been shown to cause programmed cell death in melanoma cell lines and may be a potential anti-tumor agent.

**TECHNICAL INFORMATION**

**Chemical Formula:** C_{23}H_{18}ClF_{2}N_{3}O_{3}S

**CAS Number:** 918504-65-1

**Molecular Weight:** 489.92

**Purity:** >98%

**Appearance:** a crystalline solid

**Solubility:** DMSO

**REFERENCES**